AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Haleon PLC

Board/Management Information Sep 28, 2023

5111_dirs_2023-09-28_83ed9e2a-f8e0-4309-a283-7703f2636f49.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 0125O

Haleon PLC

28 September 2023

Haleon plc: Director Declaration

28 September 2023: In accordance with paragraph 9.6.14R of the Listing Rules of the UK Financial Conduct Authority, Haleon plc (the "Company") (LSE/NYSE: HLN) notes that Deirdre Mahlan, an Independent Non-Executive Director and Chair of the Audit & Risk Committee of the Company has been appointed Interim President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc. (NYSE: NAPA) with immediate effect from 27 September 2023.

There is no further information to be disclosed in respect of paragraph 9.6.14.

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNLPMLTMTJTMFJ

Talk to a Data Expert

Have a question? We'll get back to you promptly.